NDAORALCAPSULEPriority Review
Approved
May 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PYTEST is an oral capsule formulation of Urea C-14, a radioactive diagnostic agent used to detect Helicobacter pylori infection in the gastrointestinal tract. The product works by allowing patients to ingest labeled urea that is metabolized by H. pylori bacteria, producing labeled CO2 that is measured in breath samples. This is a non-invasive diagnostic test rather than a therapeutic agent.
LOE Approaching
Product is approaching loss of exclusivity with limited commercial opportunity; team size likely minimal and defensive in posture.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and a product in LOE-approaching lifecycle, this asset offers minimal career growth or mobility opportunities. Roles are likely maintenance-focused rather than growth-oriented, suitable only for experienced professionals managing declining portfolios.
Specialty Sales RepresentativeDiagnostic Sales Manager
Worked on PYTEST at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.